Those investors who are currently looking into the possibility of investing in biopharmaceutical stocks could do well to take a look at the Atossa Therapeutics (NASDAQ:ATOS) stock. It has emerged as one of the major gainers so far this year despite having performed poorly in recent week. Over the course of the past month, the …
Continue reading “Atossa Therapeutics (NASDAQ:ATOS) Stock Falls Sharply From The Recent Peak”
Investors can attempt to trade clinical-stage biopharmaceutical firm Atossa Therapeutics (NASDAQ:ATOS) either by buying or holding the shares. Shares of the firm have moon-shot potential with users targeting low-priced scripts, especially for short-term trades. Long-term investors can consider the firm based on bigger picture of breakthrough medicine progress. The firm does appear to be on the …
Continue reading “Atossa Therapeutics (NASDAQ:ATOS) Stock Slips Below $4: Should You Buy Or Ignore?”
The COVID 19 pandemic might be abating but companies are still working on treatments for it and one of the companies that has garnered considerable attention from investors due to its work on a COVID 19 treatment is Atossa Therapeutics (NASDAQ:ATOS). There are two things to consider with regards to the Atossa stock. First of …
Continue reading “Atossa Therapeutics (NASDAQ:ATOS) Stock Slips Over 50% From The Peak: A Good Buy?”
Atossa Therapeutics Inc. (NASDAQ:ATOS) stock has been among the top-performing stocks this year, and it is up 565% year to date. The Hyman Research Ethics Committee (HREC) gave the company regulatory approval to start a clinical trial for AT-H201 in Australia. At-H201 is a nebulized formulation the company is developing as an inhaler for hospitalized …
Continue reading “Atossa Therapeutics Inc. (NASDAQ:ATOS) stock Rockets 565% YTD: Will it Hot $10?”
